Aslan Pharma, a Singapore oncology company, announced the US FDA has concluded its 30-day review of Aslan’s IND application for ASLAN003. The company plans to evaluate the candidate in the US as part of an ongoing Phase II trial of ASLAN003 in patients with acute myeloid leukemia. Trials are already underway in Singapore and Australia. Aslan believes ASLAN003, an oral inhibitor of DHODH, has the potential to be a first-in-class drug. It has Orphan Drug Designation in the US and Europe.
Source: China Biotoday
